Product Information
RIVASTIGMINE 3 MG CAPSULE is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.1458 per EA under NDC 62332006460. Its NADAC has been published 217 times since Aug 10, 2022.
FDA first approved this application on Jun 12, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3 mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332006460
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIVASTIGMINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA091689FDA Approved
6/12/2012
TE Code
AB
On Market Since
6/12/2022
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 3 MG CAPSULE has been published 217 times since Aug 10, 2022, and over the history we have for it it has declined 31.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1458 per EA |
|---|---|
| All-time high | $0.2557 (Jan 11, 2023) |
| All-time low | $0.1451 (Jul 17, 2024) |
| 52-week high | $0.1853 |
| 52-week low | $0.1458 |
| Median price | $0.1951 |
| Average price | $0.1940 |
| Largest weekly change | +26.4% (Nov 22, 2023) |
| Weeks tracked | 217 |
| Tracking since | Aug 10, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rivastigmine Tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 3 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 3 MG CAPSULE, manufactured by Alembic Pharmaceuticals Inc., is $0.1458 per EA (NDC 62332006460), effective Sep 30, 2026.
How has the price of RIVASTIGMINE 3 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 3 MG CAPSULE has declined 31.2%. It has been tracked across 217 weekly CMS publications since Aug 10, 2022.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 3 MG CAPSULE?
Since Aug 10, 2022, the NADAC for RIVASTIGMINE 3 MG CAPSULE has ranged from a low of $0.1451 (Jul 17, 2024) to a high of $0.2557 (Jan 11, 2023), with a median of $0.1951 per EA.
Are there cheaper alternatives to RIVASTIGMINE 3 MG CAPSULE?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 3 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVASTIGMINE 3 MG CAPSULE?
RIVASTIGMINE 3 MG CAPSULE (NDC 62332006460) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.